[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Samara State Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,70,94,124,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100511727","clinical-and-microbiological-approach-in-orthopedic-treatment-of-patients-when-choosing-a-structural-material-100511727",false,"NCT05943197","Clinical and Microbiological Approach in Orthopedic Treatment of Patients When Choosing a Structural Material","Inclusion Criteria:\n\n\\- need for prosthetics\n\nExclusion Criteria:\n\n\\- lack of indications for treatment","ALL","1 Month",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"NA","Today, there is a wide range of structural materials on the market, different in chemical, physical and biological properties, and information about them is very often limited only by the manufacturer's instructions, which allows to determine, at best, only the scope. In this regard, there are difficulties in choosing the optimal material for this particular situation, since without a thorough approach to studying the properties of the main materials used in dentistry, it seems difficult to provide high-quality dental care, the result of which is functional usefulness, aesthetics and durability.The problem of an individual approach to the choice of structural material from the standpoint of personalized medicine is even less studied - there are no data in the literature on the role of normal and pathogenic microflora in the development of destructive changes in structures and the development of complications, taking into account a personalized approach when analyzing the composition of the microbiota of the oral cavity, biochemical parameters of the oral fluid, blood depending on the material from which the structure is made.",[25],"Oral Microbiota",[27],"microbiota","RECRUITING","2024-12-31",{"date":31,"type":32},"2025-01-01","ACTUAL",{"date":34,"type":32},"2023-06-01",{"date":36,"type":19},"2025-04-01",{"name":38,"class":39},"Samara State Medical University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100495670","optimization-of-surgical-treatment-of-patients-with-incisional-ventral-hernias-100495670","NCT05734222","Optimization of Surgical Treatment of Patients With Incisional Ventral Hernias","Optimization of Surgical Treatment of Patients With Postoperative Median and Median-lateral Ventral Hernias","Inclusion Criteria:\n\n* The study will include patients with postoperative ventral hernias of median and lateral localization and an average hernial gate width from 4.1 to 15 cm (W2-W3 according to the EHS classification).. The size of the hernial gate is determined by CT.\n\nExclusion Criteria:\n\n* Patients without postoperative ventral hernias median and lateral localization","25 Years","88 Years",{"count":51,"type":19},110,[22],"The goal of our work of optimization of the treatment of postoperative hernias is to improve the results of treatment of patients with median and median-lateral postoperative hernias of medium (W2) and large (W3) sizes by developing new surgical techniques. The main questions it aims to answer are:\n\n1. To study the topographic and variant anatomy of vessels and nerves in the retromuscular, preperitoneal, postperitoneal and pre-abdominal cell spaces of the anterior abdominal wall. To determine the most probable sources of blood flow and lymph from the anatomical formations forming the bed of the endoprosthesis.\n2. To develop technical, surgical techniques that allow to form an implant bed with minimal traumatization of blood vessels and nerves and reduce the risk of postoperative complications.\n3. To develop a technique for plasty of the anterior abdominal wall in mid-lateral postoperative hernias with a combination of retromuscular and subaponeurotic spaces.\n\nThe researchers will compare an experimental group in which a new method of preparing the implant place will be used and a control group in which standard methods of treating postoperative ventral hernias were used to see whether the new method affects the improvement of the postoperative period and the reduction of complications.",[55,56,57],"Hernia, Ventral","Hernias Intestinal","Hernia Abdominal Wall",[59,60,61,62,63],"Hernia","median","median-lateral","median-lateral Incisional hernia","Incisional",{"date":31,"type":32},{"date":66,"type":32},"2022-09-29",{"date":68,"type":19},"2025-05-23",{"name":38,"class":39},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100497522","vibropneumostimulation-in-the-rehabilitation-after-dental-implantation-100497522","NCT05758337","Vibropneumostimulation in the Rehabilitation After Dental Implantation","Clinical and Functional Rationalization of the Use of Vibropneumostimulation in the Rehabilitation System of Patients After Dental Implantation","Inclusion Criteria:\n\n* patients with a history of previous unsuccessful implantations,\n* patients with a history of bad habits,\n* patients with low bone density (CT),\n* patients who have sinus lifting surgery performed simultaneously\n\nExclusion Criteria: No\n\n\\-",{"count":78,"type":19},100,[22],"A new comprehensive technique of dental implantation and rehabilitation of patients will be developed and theoretically justified, including an individual dental implant of a dowel system made of non-woven titanium material with through porosity and vibropneumostimulation, which will improve the functional and anatomical results of treatment.\n\nIn the complex treatment and rehabilitation of patients after dental implantation, a vibropneumostimulator with vibratodes of its own design will be used, which activate bone remodeling, which will expand the practical application and theoretical knowledge in the field of hardware massage.",[82],"Dental Implantation",[84,85],"dental implantation","vibropneumostimulation","2024-12-12",{"date":88,"type":32},"2024-12-13",{"date":90,"type":32},"2022-09-01",{"date":92,"type":19},"2025-09-01",{"name":38,"class":39},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100491730","condition-vasoregulation-function-endothelium-in-patients-with-cml-getting-tki-ii-generation-bosutinib-100491730","NCT05682924","Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","Condition Vasoregulation Function Endothelium in Patients With Chronic Myeloid Leukemia (CML) Getting Tyrosine Kinase Inhibitor (TKI) II Generation Bosutinib","Inclusion Criteria:\n\n* patients with ph-positive chronic myeloid leukemia in the chronic phase before treatment and taking tyrosine kinase inhibitors of I and II generations (imatinib, nilotinib, bosutinib);\n* availability of informed consent of the patient to participate in the study.\n\nExclusion Criteria:\n\n* history of acute cerebrovascular accident;\n* previous myocardial infarction in anamnesis;\n* the presence of diabetes mellitus type I and II;\n* the presence of chronic kidney disease C1-C5 stages;\n* the presence of coronary heart disease with its clinical manifestations (II-IV functional class);\n* the presence of hypertension III degree;\n* the presence of atherosclerotic lesions of peripheral arteries according to the color duplex sonography data of the arteries of the upper and lower extremities;\n* atrial fibrillation and flutter;\n* the presence of other oncological diseases;\n* inflammatory diseases in the acute stage;\n* the presence of mutations, in which the appointment of tyrosine kinase inhibitors of the I or II generation is not indicated (resistance to tyrosine kinase inhibitors drugs)\n* refusal of the patient from examination.","40 Years","60 Years",{"count":104,"type":19},105,"OBSERVATIONAL","The study will study the state of the endothelium in patients with chronic myeloid leukemia during therapy with the II generation tyrosine kinase inhibitor bosutinib. Patients will be divided into groups receiving nilotinib 800mg\u002Fday, bosutinib 500mg\u002Fday, and imatinib 600mg\u002Fday. A comprehensive examination of patients will be carried out, including a clinical examination, a study of biochemical markers of endothelial damage and the functional state of the vascular wall. An algorithm will be developed for assessing the state of endothelial function in patients with ph-positive chronic myeloid leukemia in the chronic phase when using the second-generation tyrosine kinase inhibitor bosutinib.",[108],"Chronic Myeloid Leukaemia",[110,111,112,113,114],"chronic myeloid leukaemia","tyrosine kinase inhibitor","endothelium","endothelial dysfunction","bosutinib","2024-12-10",{"date":117,"type":32},"2024-12-16",{"date":119,"type":32},"2022-10-01",{"date":121,"type":19},"2025-09-15",{"name":38,"class":39},2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":15,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":20,"phases":134,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":40},"100500945","phase-4-acetazolamide-per-os-for-decompensation-of-heart-failure-100500945","NCT05802849","Acetazolamide Per os for Decompensation of Heart Failure","ORION-A","Inclusion Criteria:\n\n* Men or women aged 18 years and older\n* Decompensated CHF NYHA II-IV, which required intravenous administration of diuretics\n* Any injection fraction of left ventricle\\*\n* Signed informed consent to participate in the study.\n\n  * in patients with LV LV ≥ 50%: the presence of structural changes of the heart# (left ventricular myocardial hypertrophy, enlargement of the left atrium) and\u002For diastolic dysfunction# and\u002For increased levels of BNP or NT-proBNP (BNP \\> 400 pg\u002Fml or NT-proBNP \\> 450 pg\u002Fml in persons younger 50 years old; \\> 900 pg\u002Fl in persons 51-75 years old; \\> 1800 pg\u002Fml older than 75 years) #.\n\n    * criteria according to clinical guidelines 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829\u002F1560-4071-2020-4083\n\nExclusion Criteria:\n\n* Acetazolamide therapy for a month before hospitalization.\n* The expected intravenous use of inotropes, vasopressors or sodium nitroprusside at any time of the study.\n* Exposure to nephrotoxic agents (e.g. contrast dye) is expected within the next 3 days.\n* Hypersensitivity to acetazolamide, other sulfonamides and \u002F or components of the drug.\n* Systolic blood pressure \\\u003C90 mmHg.\n* Pregnancy and lactation.\n* Hypokalemia (potassium \\\u003C 3.5 mmol\u002Fl).\n* Hyponatremia (sodium \\\u003C135 mmol\u002Fl).\n* Severe chronic renal insufficiency (creatinine clearance less than 10 ml\u002Fmin) or the use of renal replacement therapy or ultrafiltration at any time prior to inclusion in the study.\n* Metabolic acidosis (bicarbonate less than 12 mmol\u002FL).\n* Severe anemia (Hb \\\u003C70 g\u002FL).\n* Acute renal failure.\n* Addison's disease.\n* Decompensated diabetes mellitus.\n* Emergency conditions (myocardial infarction, pulmonary embolism, acute myocarditis, pericarditis, aortic aneurysm).\n* Cirrhosis of the liver with encephalopathy and liver failure.\n* Congenital heart defects.\n* Malignant neoplasm in the phase of active treatment or terminal form of cancer.\n* Hypocorticism.","18 Years",{"count":133,"type":19},400,[135],"PHASE4","The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually.\n\nAcute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.",[138],"Chronic Heart Failure",[140,141],"acetazolamide","edema syndrome","2024-11-02",{"date":144,"type":32},"2024-11-05",{"date":146,"type":32},"2023-05-01",{"date":148,"type":19},"2025-12-01",{"name":38,"class":39},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":131,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":20,"phases":159,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":40},"100493282","clinical-and-diagnostic-significance-of-endothelial-dysfunction-and-myocardial-contractility-in-patients-with-aml-100493282","NCT05703126","Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML","Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With Acute Myeloid Leukemia","Inclusion Criteria:\n\n* patients with acute myeloid leukemia receiving anthracycline-containing polychemotherapy regimens aged 18 to 65 years, without clinical signs of heart failure, with an LV ejection fraction of more than 50% before starting chemotherapy;\n* availability of informed consent of the patient to participate in the study.\n\nExclusion Criteria:\n\n* acute violation of cerebral circulation in history;\n* a history of myocardial infarction;\n* the presence of diabetes mellitus type I and II;\n* the presence of chronic kidney disease C1-C5 stages;\n* the presence of stable angina III-IV functional classes;\n* the presence of unstable angina pectoris;\n* the presence of atrial fibrillation and flutter;\n* the presence of arterial hypertension of 2-3 degrees;\n* the presence of other oncological diseases;\n* inflammatory diseases in the acute stage;\n* diseases of the thyroid gland;\n* therapy with any monoclonal antibodies in history;\n* a positive test for the presence of HIV and hepatitis B and C;\n* alcoholism, drug addiction;\n* the presence of neuroleukemia, extramedullary foci of leukemia;\n* refusal of the patient to be examined.\n* the emergence of life-threatening situations during the study;\n* development in patients of diseases related to the non-inclusion criteria;\n* refusal of the patient to further examination.","65 Years",{"count":78,"type":19},[22],"Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of immature myeloid cells.\n\nAnthracycline antibiotics have been an integral part of the treatment of acute myeloid leukemia since the 1970s. However, the clinical usefulness of anthracyclines is limited primarily by the high incidence of cardiotoxicity. According to the European Society of Cardiology guidelines for cardio-oncology, cardiovascular toxicity is defined as any impairment of cardiac function associated with anticancer treatment, as the term encompasses both a wide range of possible clinical manifestations and an etiological relationship with various treatments, including chemotherapy, radiation therapy, immunotherapy and treatment with targeted drugs. Cardiovascular toxicity can be acute, subacute or delayed, manifesting many years after chemotherapy or radiation therapy, involving a number of cardiac structures, which can lead to the development of heart failure, coronary heart disease, valvular heart disease, arrhythmias, including cardiac conduction disorders and diseases of the pericardium.\n\nAnthracycline-induced cardiotoxicity is the negative effect of anthracyclines on normal cardiac activity due to their toxic effects on the heart muscle and the cardiac conduction system. Anthracycline-induced cardiotoxicity manifests as asymptomatic left ventricular dysfunction in 57% of treated patients and restrictive or dilated cardiomyopathy leading to congestive heart failure (CHF) in 16% to 20% of patients. Anthracycline-induced congestive heart failure is often resistant to therapy and has a mortality rate of up to 79%. Thus, there is a need for early detection of cardiovascular dysfunction associated with chemotherapy treatment of acute myeloid leukemia in order to timely prescribe drug therapy.\n\nPurpose of the study To optimize the early detection of endothelial dysfunction and left ventricular myocardial contractility in patients with acute myeloid leukemia during chemotherapy treatment based on a comprehensive assessment of instrumental and laboratory research parameters.\n\nExpected results Based on a comprehensive analysis using laser Doppler flowmetry, stress echocardiography with the determination of global longitudinal strain of the myocardium, biochemical markers of endothelial damage and cardiac biomarkers, a correlation between violations of the contractility of the left ventricular myocardium and violations of the vasoregulatory function of the vascular endothelium will be revealed, which will allow developing an algorithm for early detection of cardiomyopathy and vascular complications in patients with acute myeloid leukemia during chemotherapy treatment.",[162,163,164],"Acute Myeloid Leukemia, Adult","Cardiotoxicity","Endothelial Dysfunction",[166,163,164,167,168],"Acute Myeloid Leukemia","Polychemotherapy","Anthracyclines",{"date":144,"type":32},{"date":171,"type":32},"2022-12-01",{"date":173,"type":19},"2025-08-03",{"name":38,"class":39},""]